Antibody-Drug Conjugates for Cancer Therapy
Antibody–drug conjugates (ADCs) are a relatively new class of anticancer agents designed to combine the selectivity of monoclonal antibodies with cell killing properties of chemotherapy. The first ADC approved for treatment of malignancy was gemtuzumab ozogamicin, which was approved 20 years ago for treatment of CD33-positive acute myeloid leukemia. Since then, a number of ADCs were approved for management of other hematologic malignancies including other subtypes of leukemias, lymphomas, and multiple myeloma. In the solid tumor arena, a number of ADCs have been approved for usage by the FDA over the past decade, and these agents are now incorporated into the routine management of advanced urothelial cancer as well as various subtypes of breast cancer. In this session, we will discuss the pharmacological properties of recently approved ADCs, as well as the literature associated with the approval of these agents. We will also learn about a number of ADCs that are currently in clinical development.
Alexandre Chan, PharmD, MPH, FCCP, FISOPP, BCPS, BCOP, APh
Biosimilars: What’s in the Pipeline
The term biosimilar is a biological medical product that is highly similar to another already approved biologic reference medication. Expiration of patents covering biopharmaceuticals, has provided opportunities for pharmaceutical companies to develop, produce, and market biosimilars or follow-on biologicals. Due to this new regulatory pathway, biosimilars are now available to help reduce the healthcare costs associated with the use of biologics. Although biosimiliar utilization has steadily increased over the past few years with new products coming to market, overall bisoimiliar utilization is behind historic projections. Now as we look ahead to oncology biosimiliar products in development, we can get a better understand of what impact these medications will continue to make across the treatment landscape.
Ryan Haumschild, PharmD, MS, MBA
Optimizing Patient Education of Oncology Medications
Over the past decade, the management of patients with cancer has become increasingly complex with the advent of novel therapeutic modalities and combinations. Additionally, oral oncolytics play a significant role across the cancer care spectrum and allow providers to treat cancer as a “chronic” condition within the home. Cancer care requires a multidisciplinary approach to ensure optimal safety and outcomes. Patients play a crucial role in their care, especially those on oral chemotherapy. This session will focus on optimizing strategies that have led to successful patient understanding and management of their therapy. We will review the role of the oncology pharmacist in patient education and provide various resources to aid in facilitating patient and caregiver understanding.
Kirollos S. Hanna, PharmD, BCPS, BCOP
Hepatitis B Virus Screening and Management for Patients With Cancer
In the United States, chronic hepatitis B virus (HBV) infection has a prevalence of less than 1%, but the prevalence of past HBV can be 5% to 40% in high-risk populations. All patients with newly diagnosed cancer who will receive systemic anticancer therapy should be tested for HBV by three tests prior to starting therapy. Join a discussion of the latest literature and guideline recommendations for HBV screening in the patient with cancer. Discussants will cover the interpretation of hepatitis B positive results and management of these results as well as active HBV infection. Case examples and clinical experiences will heighten the applicability of HBV management to your practice.
Jolynn K. Sessions, PharmD, BCOP; Ila M. Saunders, PharmD, BCOP
Combination Therapy for Metastatic Lung Cancer
Lung cancer is the leading cause of cancer-related mortality worldwide with non-small cell lung cancer (NSCLC) accounting for 84% of all lung cancer diagnoses. The goal of this talk is to provide an update on new immunotherapy approvals in the non-small cell lung cancer space. The content will be delivered with the use of a patient case scenario to discuss key decision-making points that should be considered in choosing between immunotherapy regimens. This includes some of the subtle differences in study design between registry trials that may influence the results of the trial and subsequently the generalizability of the data.
Val R. Adams, PharmD, FHOPA, FCCP, BCOP
Approaches for Neoadjuvant Therapy for Resectable/ Borderline Resectable Pancreatic Cancer
Pancreatic cancer is the tenth leading cause of cancer in men and eighth leading cause of cancer in women in the United States. Unfortunately, due to the aggressive nature of this disease and lack of effective screening modalities well over 50% of Americans are diagnosed with incurable distant or metastatic disease. Of those patients diagnosed with local or regional disease, the approach to treatment will fall into one of three categories: resectable, borderline resectable, or locally advanced disease. The use of systemic therapy in the management of resectable or borderline resectable pancreatic cancer has been a standard of care especially in the adjuvant setting. However, the utilization of neoadjuvant therapy and the optimal regimen to be utilized in this setting is controversial. This session will focus on indications and modalities for neoadjuvant therapy in resectable and borderline resectable pancreatic cancer as well as a discussion of the optimal regimen and duration of therapy.
Salvatore M. Bottiglieri, PharmD, BCOP
Sequencing of Therapy in Metastatic Urothelial Cancer and Therapy for Cisplatin-Ineligible Patients
For many years, the treatment of metastatic urothelial cancer was limited to cisplatin- based regimens and for those who were cisplatin ineligible, few effective options existed. More recently treatment of metastatic urothelial cancer has evolved with the introduction of immune checkpoint inhibitors, drug-antibody conjugates, and targeted therapy. Thus, understanding optimal sequencing has become a hot topic. Within this session, the data supporting preferred first-line and subsequent-line regimens will be presented, focusing on optimal sequencing, as well as the option for those patients that are cisplatin-ineligible.
Lisa Holle, PharmD, BCOP, FHOPA, FISOPP
Standard of Care: FCR
The approval of targeted therapies, including BTK-inhibitors and venetoclax, has led to a rapid shift in the treatment paradigm for frontline management of CLL and prompted questions surrounding the utility of the standard FCR (fludarabine, cyclophosphamide, and rituximab) regimen. This session will dive into case-based scenarios highlighting the place in therapy for both chemo-immunotherapy as well as the newer targeted options. After attending, participants should be able to identify which patient-specific characteristics should be considered when determining the most appropriate frontline treatment option.
Kelly Valla, PharmD, BCOP; Alexandra Lovell, PharmD, BCOP